Peer Exchange

Formulary Access to Insulins in Type 2 Diabetes
August 29, 2017 – 
Mark Warren, MD, emphasizes the importance of formulary access to the insulin therapies prescribed and the role of biosimilar insulins in type 2 diabetes.
Deciding Among Insulin Therapies for Type 2 Diabetes
August 29, 2017 – 
Mark Warren, MD, explains some of the key benefits associated with the ultra–long acting insulins and shares his clinical rationale for switching therapies in type 2 diabetes.
Practical Decisions in Type 2 Diabetes
August 22, 2017 – 
Mark Warren, MD, shares how he makes type 2 diabetes treatment decisions and explains the link between regimen complexity, compliance, and resource utilization.
Barriers to Insulin Therapy in Type 2 Diabetes
August 22, 2017 – 
Mark Warren, MD, provides an overview of some of the key barriers to initiating insulin therapy in patients with type 2 diabetes.
Role of GLP-1/Insulin Combinations
August 15, 2017 – 
Louis S. Christos, RPh, offers a payer perspective regarding the role of glucagon-like peptide-1 receptor agonist/insulin combinations and discusses the importance of real world evidence.
The Future of Healthcare in the United States
August 14, 2017 – 
Panelists Joseph Alvarnas, MD; Robert Carlson, MD; Elizabeth Carpenter; and John Fox, MD, provide further expectations for the future of value-based oncology care.
How Will an ACA Repeal Affect Healthcare?
August 14, 2017 – 
Leonard Lichtenfeld, MD, shares insight on the impact of repealing the Affordable Care Act.
Results From the CANVAS Trial
August 10, 2017 – 
John B. Buse, MD, PhD, reviews the efficacy and safety findings from the CANVAS study of canagliflozin in patients with type 2 diabetes.
Impact of EMPA-REG OUTCOME
August 10, 2017 – 
John B. Buse, MD, PhD, discusses the efficacy and safety findings from the EMPA-REG OUTCOME trial with empagliflozin in patients with type 2 diabetes.
Formulary Decisions and GLP-1/Insulin Combinations
August 08, 2017 – 
Louis S. Christos, RPh, outlines some of the potential benefits associated with glucagon-like peptide-1 (GLP-1) receptor agonist/insulin fixed-ratio combinations.
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome to the new and improved AJMC.com, the premier managed markets network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!